Navigation Links
EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
Date:8/27/2013

ti is among the world's 50 most-cited researchers and an influential figure in cell biology and cancer research. Dr. Ruoslahti’s work has clarified many of the fundamental mechanisms responsible for clinically relevant problems, including tumor metastasis, blood clotting and immune cell homing. His research spawned many drug-discovery programs, some of which have resulted in FDA-approved drugs.

         For more information on EnduRx Pharmaceuticals, visit the company’s website here. Information regarding ACTUS Biotechnologies may be found at the company’s website, here. Additional information on the Rocky Mountain Life Science Investor and Partnering Conference can be found here.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11063745.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") ... collaborative research program with Emerald Logic, a ... Evolution Technology (FACET), Emerald Logic analyzed Resverlogix,s ... from each of 798 patients who participated ... ASSERT, SUSTAIN and ASSURE. The objective of ...
(Date:3/4/2015)... , March 4, 2015 Vegalab announced the ... August of last year. As part of the acquisition, ... Koo continuing his role as CEO for the ... Vegalab S.A., will work alongside Koo and oversee developments ... http://photos.prnewswire.com/prnh/20150303/179218 Koo founded Ecowin ...
(Date:3/3/2015)... SAN DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - ... company developing new therapeutics and molecular diagnostics that target ... for the quarter and seventh-month period ended December 31, ... changed its fiscal year end from May 31 to ... periods we are reporting today are for the quarter ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) ... Market, 2015 - 2025" report to their offering. ... provides an extensive study on the marketed and pipeline ... out in this field for over a decade but ... Asian markets; one approved in the EU). There are ...
Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
... Texas, Feb. 6, 2012 Dietary supplements are subject ... the United States, according to a new report published ... article notes numerous authorities to regulate dietary supplements ... Administration (FDA) and the Federal Trade Commission (FTC), as ...
... UV Flu Technologies, Inc. ( OTCBB: UVFTD ) ... schedule in its continuing program to eliminate all debt. On February ... and final convertible note, in the amount of $32,500 would be ... made in the last twelve months is nothing short of extraordinary," ...
... , a Manchester team lead by Nobel laureates Professor Andre ... dimension in graphene research. Their research shows a transistor that ... next silicon. Graphene one atomic plane of ... from electronic to chemical and from optical to mechanical. ...
Cached Biology Technology:Dietary Supplements Extensively Regulated, Say Authors of New Article 2Dietary Supplements Extensively Regulated, Say Authors of New Article 3Dietary Supplements Extensively Regulated, Say Authors of New Article 4Dietary Supplements Extensively Regulated, Say Authors of New Article 5UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 3Graphene electronics moves into a third dimension 2
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
(Date:2/25/2015)... 25, 2015  ABC Financial Services (ABC), the ... Health and Fitness Industry, today announced enhancements to ... The latest upgrade includes advances to the agreement ... check-in via Identity One fingerprint biometrics. The features ... interactive displays at the International Health, Racquet & ...
(Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2
... member of the Roche group, and a Yale School ... the company’s Genome Sequencer™ system to identify previously undetectable ... earlier performed clinical trial. The work, presented today ... of Medicine and the VA CT Health Care System, ...
... copepods because they prefer to eat colonies of phytoplankton. ... the carbon cycle of cold-water oceans may be a lot ... June 11 in the online version of Proceedings of the ... a common species of saltwater algae – also known as ...
... water, including sports drinks, when exercising, a practice ... types of endurance exercise at risk of potentially ... disorders of water metabolism. Such exercise includes marathons, ... condition, known as exercise-induced hyponatremia (EAH), could be ...
Cached Biology News:454 sequencing identifies HIV drug resistance at early stage 2Marine phytoplankton changes form to protect itself from different predators 2Marine phytoplankton changes form to protect itself from different predators 3Marine phytoplankton changes form to protect itself from different predators 4Runners -- Let thirst be your guide 2Runners -- Let thirst be your guide 3Runners -- Let thirst be your guide 4
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
... Gia-1. Strong reactivity ... bovine (74%) and guinea pig ... human (31%). Specificity confirmed ... Gat, rat Goa, rat Gia-1, ...
KV beta.1 (Q-13)...
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
Biology Products: